ClinicalTrials.gg
CompletedNCT06013241BiRChUpdated Nov 4, 2026

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

A Phase 2 interventional study of Brensocatib and Placebo in Chronic Rhinosinusitis Without Nasal Polyps, sponsored by Insmed Incorporated. Completed at 100 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
10th of 71
288 · median 60
Started
2023
with 4 others
Phase 2
15 of 83
none open now
Registered
64th of 83
by date

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 10th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2023, is one of 15 in phase 2, and was the 64th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.

03

Conditions studied

  • Chronic Rhinosinusitis Without Nasal Polyps

Keywords

  • CRSsNP
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have at least a 12-week history before Screening Visit of CRSsNP and confirmed by endoscopy at Visit 1 (Screening).
  • Participants must have a NCS of ≥2 at Visit 1 (Screening Visit) and Visit 2 (Baseline; average score in the week prior to randomization).
  • Participants must have sTSS (nasal congestion [NC], anterior/posterior rhinorrhea, facial pain/pressure) ≥5 at Visit 1 (Screening) and at Visit 2 (Baseline; average score in the week prior to randomization).
  • Participants who have at least 1 of the 3 following features:

    1. Previous sinonasal surgery for CRS, including but not limited to fenestrated endoscopic sinus surgery and balloon sinuplasty.
    2. Received medical treatment with systemic (SCS) to treat symptoms of CRS as defined by any dose and duration within 1 year of Screening Visit or intolerance/ to SCS.
    3. Received a course of antibiotics to treat symptoms of CRS within 1 year before the Screening Visit.
  • Participants who have a blood eosinophil count ≤750 cells/microliter (μL) at Visit 1 (Screening).
  • Participants who have bilateral inflammation of paranasal sinuses in the CT scan performed during Screening and bilateral ethmoid and/or maxillary opacification before randomization as confirmed by the central reader.
  • Participants who have a SNOT-22 score of ≥20 at Visit 1 (Screening) and Visit 2 (Baseline).
  • Participants who have received a stable daily dose regimen of MFNS for at least 4 weeks before Visit 2 (Baseline).

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of unilateral or bilateral chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Clinical diagnosis of cystic fibrosis (CF) or primary ciliary dyskinesia.
  • Scheduled sinus surgery at any time during the study.
  • Participants who have had nasal surgery within 4 weeks before Visit 1 (Screening) and during the Screening Period.
  • Significant oral maxillofacial structural abnormalities or severe septal deviation.
  • Participants with radiological suspicion or confirmed invasive fungal rhinosinusitis, odontogenic sinusitis, osteomas, or nasal tumors.
  • Participants with acute change in symptoms consistent with acute rhinosinusitis.
  • Participants with seasonal allergic rhinitis whose symptoms coincide with the treatment period of the study.
  • Participants with moderate to severe atopic dermatitis requiring treatment with high potency topical or topical calcineurin inhibitors or biologics.
  • Clinical diagnosis of Papillon-Lefèvre syndrome.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    Brensocatib 40 mg

    Participants received brensocatib 40 milligrams (mg) tablet, orally, once daily (QD) for 24 weeks along with mometasone furoate nasal spray (MFNS) by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.

    Drug: Brensocatib · Drug: Mometasone furoate nasal spray (MFNS)

  • Experimental
    Brensocatib 10 mg

    Participants received brensocatib 10 mg tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.

    Drug: Brensocatib · Drug: Mometasone furoate nasal spray (MFNS)

  • Placebo comparator
    Placebo

    Participants received a brensocatib-matching placebo tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.

    Drug: Placebo · Drug: Mometasone furoate nasal spray (MFNS)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in Percentage of Sinus (Maxillary and Ethmoid) Opacification as Measured by Volumetry at Week 24

    The computed tomography (CT) scan performed during Screening (considered as Baseline) and at Week 24 will be used for the volumetric assessment of maxillary and ethmoid sinus opacification.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Modified Lund-MacKay (LMK) Computed Tomography (CT) Score at Week 24

    Time frame: Baseline and Week 24

  3. Proportion of Participants Requiring Rescue (Antibiotics, Systemic Corticosteroids [SCS], and/or Nasal Surgery) due to Worsening of any Chronic Rhinosinusitis (CRS) Symptoms up to Week 24

    Time frame: Baseline up to Week 24

  4. Change From Baseline to the 28-day Average of Daily Nasal Congestion Score (NCS) at Week 24

    Time frame: Baseline and Week 24

  5. Change From Baseline to the 28-day Average of Daily Peak Nasal Inspiratory Flow (PNIF) at Week 24

    Time frame: Baseline and Week 24

  6. Change From Baseline in Sino-Nasal Outcome Test (SNOT-22) Total Score at Week 24

    Time frame: Baseline and Week 24

  7. Plasma Concentration of Brensocatib

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 24

  8. Percentage of Participants who Experienced at Least One Adverse Event (AE)

    Determination of the safety and tolerability of brensocatib compared with placebo.

    Time frame: Up to 28 weeks

07

Study locations

100 sites
  • USA034
    Tucson, Arizona 85704, United States
  • USA002
    Roseville, California 95661, United States
  • USA006
    Upland, California 91786, United States
  • USA016
    Boca Raton, Florida 33487, United States
  • USA019
    Hollywood, Florida 33024, United States
  • USA001
    Miami, Florida 33135, United States
  • USA009
    Tampa, Florida 33613, United States
  • USA031
    Chicago, Illinois 60611, United States
  • USA021
    Chicago, Illinois 60612, United States
  • USA003
    New Albany, Indiana 47150, United States
  • USA035
    Mandeville, Louisiana 70471, United States
  • USA026
    Baltimore, Maryland 21287, United States
  • USA011
    Columbia, Missouri 65212, United States
  • USA024
    St Louis, Missouri 63141, United States
  • USA033
    New York, New York 10016, United States
  • USA028
    Tulsa, Oklahoma 74132, United States
  • USA004
    Tulsa, Oklahoma 74136, United States
  • USA015
    Hershey, Pennsylvania 17033, United States
  • USA023
    Charleston, South Carolina 29425, United States
  • USA022
    North Charleston, South Carolina 29406, United States
  • USA025
    Dallas, Texas 75231, United States
  • USA037
    Fredericksburg, Texas 78624, United States
  • USA029
    Houston, Texas 77022, United States
  • USA018
    Houston, Texas 77030, United States
  • USA030
    San Antonio, Texas 78258, United States
  • USA038
    Tomball, Texas 77375, United States
  • USA005
    Norfolk, Virginia 23507, United States
  • ARG015
    La Plata, Buenos Aires B1900BNN, Argentina
  • ARG001
    La Plata, Buenos Aires B1900, Argentina
  • ARG006
    Lobos, Buenos Aires B7240AAN, Argentina
  • ARG005
    Buenos Aires, Ciudad Autónoma de BuenosAires C1121ABE, Argentina
  • ARG012
    Buenos Aires, Ciudad Autónoma de BuenosAires C1414, Argentina
  • ARG011
    Buenos Aires, Ciudad Autónoma de BuenosAires C1425, Argentina
  • ARG017
    Buenos Aires, Ciudad Autónoma de BuenosAires C1426ABP, Argentina
  • ARG013
    San Rafael, Mendoza Province M5600IBJ, Argentina
  • ARG007
    Rosario, Santa Fe Province S2013DBS, Argentina
  • ARG010
    Rosario, Santa Fe Province S2013DTC, Argentina
  • ARG004
    Rosario, Santa Fe Province S2013, Argentina
  • ARG009
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • ARG002
    Mar del Plata, B7602DCK, Argentina
  • ARG014
    Mendoza, 5500, Argentina
  • ARG003
    Mendoza, M5500CCG, Argentina
  • ARG016
    Rosario, S2002KDT, Argentina
  • ARG008
    Santa Fe, 3000, Argentina
  • AUS001
    Herston, Queensland 4029, Australia
  • AUS002
    Spearwood, Western Australia 6163, Australia
  • BEL001
    Ghent, Oost-Vlaanderen 9000, Belgium
  • BEL002
    Erpent, 5101, Belgium
  • BEL003
    Woluwe-Saint-Lambert, 1200, Belgium
  • BGR005
    Sofia, Sofia-Grad 1606, Bulgaria
  • BGR003
    Plovdiv, 4001, Bulgaria
  • BGR006
    Stara Zagora, 6000, Bulgaria
  • CAN003
    Vancouver, British Columbia V6Z 1Y6, Canada
  • CAN006
    London, Ontario N6A 4V2, Canada
  • CAN007
    Toronto, Ontario M5G 1X5, Canada
  • CAN005
    Montreal, Quebec H4A 3J1, Canada
  • CAN001
    Québec, Quebec G1S 4L8, Canada
  • CAN002
    Québec, G1V 4W2, Canada
  • CZE002
    Olomouc, Olomouc Region 779 00, Czechia
  • CZE003
    Pardubice, Pardubice Region 532 03, Czechia
  • CZE005
    Nový Hradec Králové, 500 05, Czechia
  • CZE004
    Prague, 140 59, Czechia
  • DNK004
    Hillerød, Capital 3400, Denmark
  • DNK001
    København Ø, Capital 2100, Denmark
  • DNK003
    Aarhus C, Central Jutland 8000, Denmark
  • DNK002
    Køge, Region Sjælland 4600, Denmark
  • FRA002
    Strasbourg, Bas-Rhin 67200, France
  • FRA003
    Marseille, Bouches-du-Rhône 13010, France
  • FRA001
    Nantes, Loire-Atlantique 44000, France
  • FRA004
    La Roche-sur-Yon, Vendée 85925, France
  • GER004
    Wiesbaden, Hesse 65183, Germany
  • GER009
    Leipzig, Saxony 04103, Germany
  • GER003
    Mittweida, Saxony 09648, Germany
  • GER008
    Lübeck, Schleswig-Holstein 23562, Germany
  • GER005
    Jena, Thuringia 07747, Germany
  • GER007
    Berlin, 10117, Germany
  • GER001
    Dresden, 01307, Germany
  • HUN003
    Pécs, Baranya 7621, Hungary
  • ITA001
    Rozzano, Lombardy 20089, Italy
  • ITA002
    Sassari, Sardinia 07100, Italy
  • ITA003
    Pisa, Tuscany 56124, Italy
  • POL002
    Poznan, Greater Poland Voivodeship 60-309, Poland
  • POL010
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • POL005
    Krakow, Lesser Poland Voivodeship 30-033, Poland
  • POL007
    Wieliczka, Lesser Poland Voivodeship 32-020, Poland
  • POL009
    Wroclaw, Lower Silesian Voivodeship 52-416, Poland
  • POL003
    Lublin, Lublin Voivodeship 20-954, Poland
  • POL001
    Warsaw, Masovian Voivodeship 00-189, Poland
  • POL004
    Bialystok, Podlaskie Voivodeship 15-276, Poland
  • POL006
    Katowice, Silesian Voivodeship 40-611, Poland
  • POL008
    Warsaw, 04-141, Poland
  • PRT001
    Guimarães, Braga District 4835-044, Portugal
  • PRT003
    Lisbon, Lisbon District 1349-019, Portugal
  • PRT005
    Senhora da Hora, Porto District 4464-513, Portugal
  • PRT004
    Aveiro, 3814-501, Portugal
  • PRT002
    Braga, 4710, Portugal
  • ESP003
    Santander, Cantabria 39008, Spain
  • ESP002
    Jerez de la Frontera, Cádiz 11407, Spain
  • ESP004
    Málaga, Málaga 29009, Spain
  • ESP001
    Seville, 41009, Spain
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2025, 23 months.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2023
First posted
Aug 28, 2023
StartActual
Oct 30, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Oct 30, 2025
Results delay requested
Sep 29, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, registry dates, site details, arm descriptions, contact details and references
2 updates, last Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 5 other changes: verification date, arm descriptions, site details, contact details and references
  2. Sep 30, 2026
    Minor edits only
    + 3 other changes: verification date, registry dates and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06013241
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Oct 30, 2023
Primary completion
Sep 30, 2025
Completion
Oct 30, 2025
Last update
Nov 4, 2026

Study contacts

Study Director
study director · Insmed Incorporated

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion